This article is a correction to:
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald1*
Thomas Powles2
Masatoshi Eto3Evgeny Kopyltsov4Sun Young Rha5
Camillo Porta6
Robert Motzer7
Thomas E. Hutson8María José Méndez-Vidal9
Sung-Hoo Hong10
Eric Winquist11Jeffrey C. Goh12
Pablo Maroto13
Tomas Buchler14
Toshio Takagi15Joseph E. Burgents16
Rodolfo Perini17Cixin He18Chinyere E. Okpara19Jodi McKenzie20
Toni K. Choueiri21- 1Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany
- 2Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom
- 3Department of Urology, Kyushu University, Fukuoka, Japan
- 4State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia
- 5Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
- 6Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, Italy
- 7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
- 8Medical Oncology, Texas Oncology, Dallas, TX, United States
- 9Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain
- 10Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea
- 11Department of Oncology, University of Western Ontario, London, ON, Canada
- 12ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia
- 13Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 14Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia
- 15Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
- 16Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States
- 17Clinical Research, Merck & Co., Inc., Rahway, NJ, United States
- 18Biostatistics, Eisai Inc., Nutley, NJ, United States
- 19Clinical Research, Eisai Ltd., Hatfield, United Kingdom
- 20Clinical Research, Eisai Inc., Nutley, NJ, United States
- 21Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
by Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2023) Front. Oncol. 13:1223282. doi: 10.3389/fonc.2023.1223282
In the published article, there was an error in the legend for Figure 3 and Supplementary Table 1 as published. Clarification that objective response rates and complete response rates were calculated based on the number of patients in each listed subgroup was omitted. The corrected legend of both appears below.
Figure 3
Figure 3 ORRa and Odds Ratios for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment in Subgroups of Interest. aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups. CI, confidence interval; CR, complete response; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IRC, independent review committee; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1; S, sunitinib.
“aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups.”
In the published article, there was an error in Figure 3 and Supplementary Table 1 as published. For both, percentages in the “complete response” column were incorrectly calculated as the number of patients with a complete response in each subgroup divided by all patients in the respective treatment arm (n=355 for lenvatinib + pembrolizumab; n=357 for sunitinib) instead of being divided by the number of patients in each applicable subgroup.
The corrected Figure 3 and its captions (also corrected per the above to “aAs assessed by IRC per RECIST v1.1. bPercents were calculated based on listed subgroups.”) appear below.
The text did not account for the revisions made to the complete response rate mentioned above.
A correction has been made to Section 3.2.3 (Objective response), paragraph 2. This sentence previously stated:
“As expected, the rates of CRs were higher in patients without baseline bone metastases or baseline liver metastases, in patients who had baseline lung metastases, and in patients who had a prior nephrectomy. While the number of patients with sarcomatoid features was small, the rates of CRs in patients without sarcomatoid features was higher than those of patients with sarcomatoid features.”
The corrected sentence appears below:
“As expected, the rates of CRs were higher in patients without baseline bone metastases, and in patients who had a prior nephrectomy. CR rates were similar irrespective of whether or not patients had baseline liver metastases.”
The Supplementary Table 1 has been updated directly in the original article.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: renal cell carcinoma, lenvatinib, pembrolizumab, sunitinib, bone metastases, liver metastases, lung metastases, sarcomatoid histology
Citation: Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2024) Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front. Oncol. 13:1343027. doi: 10.3389/fonc.2023.1343027
Received: 22 November 2023; Accepted: 27 November 2023;
Published: 01 March 2024.
Edited and Reviewed by:
Umang Swami, The University of Utah, United StatesCopyright © 2024 Grünwald, Powles, Eto, Kopyltsov, Rha, Porta, Motzer, Hutson, Méndez-Vidal, Hong, Winquist, Goh, Maroto, Buchler, Takagi, Burgents, Perini, He, Okpara, McKenzie and Choueiri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Viktor Grünwald, VmlrdG9yLkdydWVud2FsZEB1ay1lc3Nlbi5kZQ==